{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T17:01:08Z","timestamp":1792342868354,"version":"4.4.0"},"reference-count":28,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Age-related macular degeneration (AMD) is the leading cause of blindness among people aged 50 years or older worldwide. There is a need for new strategies for the prevention and treatment of AMD. There is some limited evidence to suggest the possibility of a protective association of dementia medications with the development of some types of AMD, but the evidence is weak.<\/jats:p><\/jats:sec>Objective<\/jats:title>To investigate whether the dementia medications memantine and donepezil are associated with the risk of developing AMD.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>Three population-based cohort studies were performed using data from the Clinical Practice Research Datalink GOLD and Aurum databases from May 15, 2002, to June 21, 2022. Participants included individuals with dementia (vascular dementia, nonvascular dementia, or Alzheimer disease) aged 40 years or older. Statistical analysis was carried out between February and November 2023.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Exposures were dementia medications. Cohort 1 compared patients prescribed donepezil with those prescribed rivastigmine or galantamine using the new-user design. Cohort 2 compared memantine with donepezil, rivastigmine, or galantamine using the prevalent new-user design. In a sensitivity analysis, cohort 3 compared memantine with rivastigmine or galantamine only.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>New diagnosis of AMD.<\/jats:p><\/jats:sec>Results<\/jats:title>There were 132\u202f846 individuals (mean [SD] age, 80.4 [7.6] years; 61.8% women; mean [SD] body mass index [BMI], 25.5 [4.6]) with a diagnosis of dementia included in cohort 1, 159\u202f419 individuals (mean [SD] age, 81.2 [7.6] years; 59.7% women; mean [SD] body mass index [BMI], 25.6 [4.7]) with a diagnosis of dementia included in cohort 2, and 92\u202f328 individuals with a diagnosis of dementia included in cohort 3 (mean [SD] age, 80.9 [7.7] years; 58.5% women; mean [SD] body mass index [BMI], 25.5 [4.7]). The adjusted hazard ratio (HR) for donepezil compared with rivastigmine or galantamine (cohort 1) was 0.95 (95% CI, 0.67-1.35). The adjusted HR for memantine compared with donepezil, rivastigmine, or galantamine (cohort 2) was 1.03 (95% CI, 0.83-1.27). The adjusted HR for memantine vs rivastigmine or galantamine only (cohort 3) was 1.24 (95% CI, 0.83-1.86).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This cohort study of patients with dementia found no significant associations between memantine or donepezil compared with other dementia medications and the risk of development of AMD. Further research is recommended to examine any possible pathophysiological protective action of memantine and other dementia medications against the development of AMD.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.41166","type":"journal-article","created":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T15:32:10Z","timestamp":1729783930000},"page":"e2441166","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacologic Treatments for Dementia and the Risk of Developing Age-Related Macular Degeneration"],"prefix":"10.1001","volume":"7","author":[{"given":"Jingya","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Applied Health Sciences, University of Birmingham, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Antza","sequence":"additional","affiliation":[{"name":"Department of Applied Health Sciences, University of Birmingham, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen Hwa","family":"Lee","sequence":"additional","affiliation":[{"name":"Action Against Age-Related Macular Degeneration, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Coker","sequence":"additional","affiliation":[{"name":"Action Against Age-Related Macular Degeneration, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pearse A.","family":"Keane","sequence":"additional","affiliation":[{"name":"NIHR (National Institute for Health and Care Research) Moorfields Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and Institute of Ophthalmology, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair K.","family":"Denniston","sequence":"additional","affiliation":[{"name":"Department of Applied Health Sciences, University of Birmingham, Birmingham, United Kingdom"},{"name":"NIHR (National Institute for Health and Care Research) Moorfields Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and Institute of Ophthalmology, University College London, London, United Kingdom"},{"name":"University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom"},{"name":"Health Data Research UK, London, United Kingdom"},{"name":"NIHR Birmingham Biomedical Research Centre, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnarajah","family":"Nirantharakumar","sequence":"additional","affiliation":[{"name":"Department of Applied Health Sciences, University of Birmingham, Birmingham, United Kingdom"},{"name":"Health Data Research UK, London, United Kingdom"},{"name":"NIHR Birmingham Biomedical Research Centre, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola J.","family":"Adderley","sequence":"additional","affiliation":[{"name":"Department of Applied Health Sciences, University of Birmingham, Birmingham, United Kingdom"},{"name":"NIHR Birmingham Biomedical Research Centre, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,10,24]]},"reference":[{"issue":"6","key":"zoi241192r2","doi-asserted-by":"publisher","first-page":"e339","DOI":"10.1016\/S2214-109X(13)70113-X","article-title":"Causes of vision loss worldwide, 1990-2010: a systematic analysis.","volume":"1","author":"Bourne","year":"2013","journal-title":"Lancet Glob Health"},{"issue":"14","key":"zoi241192r3","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1056\/NEJMra062326","article-title":"Age-related macular degeneration.","volume":"355","author":"de Jong","year":"2006","journal-title":"N Engl J Med"},{"issue":"8","key":"zoi241192r6","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.ophtha.2020.12.029","article-title":"The association between vision impairment and incidence of dementia and cognitive impairment: a systematic review and meta-analysis.","volume":"128","author":"Shang","year":"2021","journal-title":"Ophthalmology"},{"issue":"1","key":"zoi241192r7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13024-022-00571-7","article-title":"Common features of neurodegenerative disease: exploring the brain-eye connection and beyond (part 2): the 2021 pre-symposium of the 15th international conference on Alzheimer\u2019s and Parkinson\u2019s diseases.","volume":"17","author":"Rossi","year":"2022","journal-title":"Mol Neurodegener"},{"issue":"3","key":"zoi241192r8","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1021\/acschemneuro.9b00242","article-title":"Pharmacological characterizations of anti-dementia memantine nitrate via neuroprotection and vasodilation in vitro and in vivo.","volume":"11","author":"Mak","year":"2020","journal-title":"ACS Chem Neurosci"},{"issue":"23","key":"zoi241192r9","doi-asserted-by":"publisher","first-page":"4224","DOI":"10.1111\/bph.14030","article-title":"Beyond symptomatic effects: potential of donepezil as a neuroprotective agent and disease modifier in Alzheimer\u2019s disease.","volume":"174","author":"Kim","year":"2017","journal-title":"Br J Pharmacol"},{"issue":"2","key":"zoi241192r11","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ophtha.2020.08.004","article-title":"Screening medications for association with progression to wet age-related macular degeneration.","volume":"128","author":"Wang","year":"2021","journal-title":"Ophthalmology"},{"issue":"3","key":"zoi241192r13","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/ije\/dyv098","article-title":"Data resource profile: Clinical Practice Research Datalink (CPRD).","volume":"44","author":"Herrett","year":"2015","journal-title":"Int J Epidemiol"},{"issue":"6","key":"zoi241192r14","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1136\/jamia.1997.0040465","article-title":"Updating the Read Codes: user-interactive maintenance of a dynamic clinical vocabulary.","volume":"4","author":"Robinson","year":"1997","journal-title":"J Am Med Inform Assoc"},{"issue":"10","key":"zoi241192r16","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1136\/bjophthalmol-2020-316820","article-title":"Geographic distributions of age-related macular degeneration incidence: a systematic review and meta-analysis.","volume":"105","author":"Zhou","year":"2021","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"zoi241192r17","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3390\/cells10010064","article-title":"The impact of oxidative stress on blood-retinal barrier physiology in age-related macular degeneration.","volume":"10","author":"Tisi","year":"2021","journal-title":"Cells"},{"issue":"6","key":"zoi241192r18","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1159\/000524942","article-title":"Pathophysiology of age-related macular degeneration: implications for treatment.","volume":"65","author":"Garcia-Garcia","year":"2022","journal-title":"Ophthalmic Res"},{"issue":"1","key":"zoi241192r19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41572-021-00265-2","article-title":"Age-related macular degeneration.","volume":"7","author":"Fleckenstein","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"zoi241192r20","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.preteyeres.2009.06.001","article-title":"Para-inflammation in the aging retina.","volume":"28","author":"Xu","year":"2009","journal-title":"Prog Retin Eye Res"},{"issue":"12","key":"zoi241192r21","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1016\/j.bbamcr.2014.09.015","article-title":"Decline in cellular clearance systems induces inflammasome signaling in human ARPE-19 cells.","volume":"1843","author":"Piippo","year":"2014","journal-title":"Biochim Biophys Acta"},{"issue":"13","key":"zoi241192r22","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.3390\/ijms20133328","article-title":"The NLRP3 inflammasome: an overview of mechanisms of activation and regulation.","volume":"20","author":"Kelley","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"2","key":"zoi241192r23","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1080\/15569527.2017.1354218","article-title":"Protective effects of melatonin and memantine in human retinal pigment epithelium (ARPE-19) cells against 2-ethylpyridine\u2013induced oxidative stress: implications for age-related macular degeneration.","volume":"37","author":"Bardak","year":"2018","journal-title":"Cutan Ocul Toxicol"},{"issue":"4","key":"zoi241192r24","doi-asserted-by":"publisher","first-page":"470","DOI":"10.18502\/jovr.v15i4.7781","article-title":"Memantine, simvastatin, and epicatechin inhibit 7-ketocholesterol\u2013induced apoptosis in retinal pigment epithelial cells but not neurosensory retinal cells in vitro.","volume":"15","author":"Neekhra","year":"2020","journal-title":"J Ophthalmic Vis Res"},{"issue":"36","key":"zoi241192r25","doi-asserted-by":"publisher","first-page":"4595","DOI":"10.2174\/09298673113209990148","article-title":"Antioxidant activity of galantamine and some of its derivatives.","volume":"20","author":"Tsvetkova","year":"2013","journal-title":"Curr Med Chem"},{"issue":"7","key":"zoi241192r26","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1042\/BCJ20200754","article-title":"Rivastigmine attenuates the Alzheimer\u2019s disease related protein degradation and apoptotic neuronal death signalling.","volume":"478","author":"Gupta","year":"2021","journal-title":"Biochem J"},{"issue":"2","key":"zoi241192r27","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1001\/jamaophthalmol.2023.6014","article-title":"Alzheimer disease treatment with acetylcholinesterase inhibitors and incident age-related macular degeneration.","volume":"142","author":"Sutton","year":"2024","journal-title":"JAMA Ophthalmol"},{"issue":"12","key":"zoi241192r28","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1016\/j.ophtha.2018.06.017","article-title":"Oral memantine for the treatment of glaucoma: design and results of 2 randomized, placebo-controlled, phase 3 studies.","volume":"125","author":"Weinreb","year":"2018","journal-title":"Ophthalmology"},{"key":"zoi241192r5","year":"2013"},{"key":"zoi241192r1","unstructured":"World Health Organization. Ageing and health. 2022. Accessed September 18, 2024. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/ageing-and-health"},{"key":"zoi241192r4","unstructured":"World Health Organization. Blindness and vision impairment. 2023. Accessed September 18, 2024. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/blindness-and-visual-impairment"},{"key":"zoi241192r10","unstructured":"Adderley? NJ, Subramanian? A, Han? JED, Gokhale? K, Nirantharakumar? K, Taverner? T. Pharmacological treatments associated with increased or decreased risk of developing age-related macular degeneration: signal detection. National Institute for Health and Care Research. 2021. Accessed September 18, 2024. https:\/\/www.cprd.com\/approved-studies\/pharmacological-treatments-associated-increased-or-decreased-risk-developing-age"},{"key":"zoi241192r12","unstructured":"Equator Network. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. 2007. Accessed August 2, 2024. https:\/\/www.equator-network.org\/reporting-guidelines\/strobe\/"},{"key":"zoi241192r15","unstructured":"Medicines & Healthcare Products Regulatory Agency. CPRD GOLD glossary of terms\/data definitions. 2023. Accessed December 13, 2023. https:\/\/www.cprd.com\/sites\/default\/files\/2023-02\/CPRD GOLD Glossary Terms v2.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2825295\/wang_2024_oi_241192_1729184093.73192.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T15:32:14Z","timestamp":1729783934000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2825295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,24]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.41166","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,24]]}}}